Prosecution Insights
Last updated: August 18, 2026

Examiner: SHARPLESS, CHRISTEN ALICIA

Tech Center 3700 • Art Units: 3795

This examiner grants 50% of resolved cases

Performance Statistics

49.5%
Allow Rate
-20.5% vs TC avg
144
Total Applications
+27.5%
Interview Lift
1210
Avg Prosecution Days
Based on 111 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
23.4%
§102 Novelty
63.6%
§103 Obviousness
12.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18452014 SCOPE DISTAL END ENCAPSULATION Final Rejection BOSTON SCIENTIFIC SCIMED, INC.
18451468 MEDICAL DEVICES AND RELATED METHODS THEREOF Non-Final OA Boston Scientific Scimed, Inc.
17852986 MEDICAL DEVICE HANDLES WITH MULTIPLE DEGREES OF FREEDOM Non-Final OA Boston Scientific Medical Device Limited
18482011 PROCESSING DEVICE, ENDOSCOPE DEVICE, AND PROCESSING METHOD Final Rejection FUJIFILM Corporation
18347572 ENDOSCOPE Final Rejection FUJIFILM Corporation
18325407 STEERABLE ENDOSCOPE WITH MOTION ALIGNMENT Final Rejection Covidien AG
17638903 SYSTEMS AND METHODS FOR USE OF STEREOSCOPY AND COLOR CHANGE MAGNIFICATION TO ENABLE MACHINE LEARNING FOR MINIMALLY INVASIVE ROBOTIC SURGERY Non-Final OA Covidien LP
18167020 INTEGRATED CABLE CONNECTOR FOR LUMINOUS EFFICIENCY Non-Final OA Cilag GmbH International
18223935 ENDOSCOPE, ENDOSCOPE SYSTEM, AND METHOD OF MANUFACTURING ENDOSCOPE Final Rejection OLYMPUS MEDICAL SYSTEMS CORP.
18219148 AUTHENTICATION METHOD FOR ENDOSCOPE, ENDOSCOPE SYSTEM, AND RECORDING MEDIUM Final Rejection OLYMPUS MEDICAL SYSTEMS CORP.
17100025 SURGICAL INSTRUMENTS WITH INTEGRATED LIGHTING SYSTEMS Final Rejection GYRUS ACMI, INC. D/B/A OLYMPUS SURGICAL TECHNOLOGIES AMERICA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month